A meta‐analysis of 23 randomized controlled trials suggested that patients treated with angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blockers (ARBs) had significantly lower incidence of AF versus those not treated with these drugs.9 The gene discussed is ACE; the disease is atrial fibrillation.